SEC Form 10-K filed by TransCode Therapeutics Inc.
$RNAZ
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
BOSTON, April 21, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the "Special Meeting") has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on April 11, 2025 (the "Special Meeting Proxy Stat
First patient in Cohort four has been treated with TTX-MC138Ten patients have been treated with TTX-MC138 at escalating dose levelsAdditional patients being evaluated for eligibility for expanded enrollmentNo significant safety or dose limiting toxicities have been reportedBOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being e
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before deducting placement agent fees and offering expenses payable by the Company.
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.
SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios. He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. "Dr. Slack is one of the most preeminent scientists in the field of small noncoding RNA," commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. "Having pioneered pivotal studies proving that microRNAs drive oncogenesis and represent critical targets for the treatment of cancer, his guidance will prove indispensable as TransCode enters the clinical phase of development." Dr. Slack is the Shields Warren Mallinckrodt Profe